Table 2.
Alteration | Heteroplastic ACF | Author | ||
---|---|---|---|---|
With sporadic CRC (%) | Serrated | Non‐serrated | ||
APC mutation | 0 (0/56) | Otori et al.( 64 ) | ||
0 (0/8) | Takayama et al.( 26 ) | |||
K‐ras mutation | 36 (10/28) | Chan et al.( 59 ) | ||
88 (28/32) | Takayama et al.( 26 ) | |||
93 (50/56) | Otori et al.( 64 ) | |||
19 (3/16) | 42 (14/33) | Rosenberg et al.( 70 ) | ||
BRAF mutation | 4 (1/26) | Beach et al.( 19 ) | ||
63 (10/26) | 3 (1/33) | Rosenberg et al.( 70 ) | ||
Chromosome 1p loss | 10 (2/20) | Chan et al.( 59 ) | ||
MGMT methylation | 13 (3/24) | Chan et al.( 59 ) | ||
CIM | 50 (14/28) | Chan et al.( 59 ) | ||
CIMP‐high | 11 (3/28) | Chan et al.( 59 ) |
CIM, CpG island methylation of MINT1, MINT2, MINT31, p16, MGMT and/or hMLH1; CIMP, CpG island methylator phenotype; CRC, colorectal cancer.